• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, August 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Study uncovers major breakthrough in understanding and treating respiratory inflammation

Bioengineer by Bioengineer
June 22, 2021
in Biology
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Common OTC drugs for sore throat causing more harm than good

IMAGE

Credit: Applied Biological Laboratories

[Brooklyn, New York] – [June 21, 2021] – Applied Biological Laboratories (Applied Bio), a biopharmaceutical company focused on the respiratory disease market, announced that its study published online in Immunology, Inflammation and Disease was able to determine the mechanism behind respiratory inflammation and treat it effectively with Biovanta(TM), a 100% naturally derived, over-the-counter (OTC) drug for cold, cough and sore throat.

The study results also showed that almost all of the leading OTC products on the market can damage the upper respiratory cells and may prolong illness. This research study and its findings represent one of the first major breakthroughs in decades for the cold and flu market.

The study, titled “A Novel Anti-inflammatory Treatment for Bradykinin-induced Sore Throat or Pharyngitis,” explored the efficacy of common OTC medications. Sore throat, or pharyngitis, is one of the most common symptoms of upper respiratory infection and a leading cause of physician visits and antibiotic prescriptions, but few, if any, OTC medications are proven to address sore throat inflammation. The randomized, blinded, placebo-controlled study utilized state-of-the-art, fully developed human respiratory tissues (organoids) grown from nasal stem cells, stimulated with a molecule called bradykinin (one of the body’s first inflammatory signals following an upper respiratory infection). Bradykinin uses Cox enzymes to stimulate more inflammatory molecules, such as prostoglandin. Once the mechanisms behind pharyngitis were understood, the cells were treated with a variety of OTC sore throat medications. Aspirin and a formula containing it as an active ingredient were also investigated as treatments and were found to be much more effective than any OTC treatment. Despite being a well-known Cox inhibitor, aspirin is not widely used for upper respiratory inflammation.

“Furthering our understanding of the mechanism behind respiratory inflammation is a key step in studying the effectiveness of common medications, and this study is profound because it also shows that ingredients commonly used in leading cough, cold and sore throat products like dextromethorphan, acetaminophen, guaifenesin and benzocaine are ineffectual and can even be toxic,” said Alan Greene, MD, practicing physician and founder of DrGreene.com. “Alternatively, this study shows that the ingredients in Biovanta offer a safe and effective treatment for inflammation vs. a reduction of the symptoms.”

Specific study results include:

  • Of the 20 OTC products tested, all but one showed inflammatory and damaging effects on at least one of the measures tested, which were: level of prostaglandin E2 (PGE2) or interleukin 8 (IL-8) – key measures of inflammation, damage to the membrane barrier as measured by the electrical resistance across it and microscopy (through a microscope), and the release of lactate dehydrogenase (LDH), a chemical that is released by cells when they die.
  • Biovanta, an OTC product with low-dose aspirin and other anti-inflammatory ingredients, reduced inflammation when applied to affected cells and tissues, making it the first scientifically proven 100% naturally derived, OTC medicine for treating cough, cold and sore throat.
  • Aspirin can lower prostaglandin levels, but there is a small therapeutic window in which aspirin is anti-inflammatory when sprayed onto cells: 6 mg per dose. Below this the drug would not have a significant affect and above it, it becomes inflammatory. For comparison, a baby aspirin contains 81 mg.

“This study is a major breakthrough in understanding the underlying mechanism of inflammation in upper respiratory illnesses, which wasn’t possible until recent scientific advancements that enabled the creation of organoids for use in testing human tissue reactions,” said Nazlie Latefi, PhD, co-founder and chief science officer, Applied Bio. “These scientifically proven results show that our groundbreaking formulas strengthen the respiratory barrier, unlike common OTC products, and we look forward to further demonstrating their effectiveness through a post-market real-world study.”

###

About Applied Biological Laboratories

Applied Biological Laboratories (Applied Bio) is a New York-based biopharmaceutical company disrupting the respiratory disease market – its products target underlying biochemical pathways and heal the respiratory system rather than mask symptoms, all with 100% natural bioactive molecules. Biovanta(TM), Applied Bio’s first product, is the only 100% natural, over-the-counter (OTC) medicine for cough, cold and sore throat. For more information, please visit http://www.appliedbioinc.com and connect on Facebook, Twitter, and LinkedIn.

Media Contact
Jessica Volchok
[email protected]

Related Journal Article

http://dx.doi.org/10.1002/iid3.479

Tags: BiochemistryHealth CareHealth ProfessionalsImmunology/Allergies/AsthmaMedicine/HealthPulmonary/Respiratory Medicine
Share12Tweet8Share2ShareShareShare2

Related Posts

blank

CK2–PRC2 Signal Drives Plant Cold Memory Epigenetics

August 2, 2025
blank

AI-Driven Protein Design Advances T-Cell Immunotherapy Breakthroughs

August 1, 2025

Melanthiaceae Genomes Reveal Giant Genome Evolution Secrets

August 1, 2025

“Shore Wars: New Study Tackles Oyster-Mangrove Conflicts to Boost Coastal Restoration”

August 1, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    41 shares
    Share 16 Tweet 10
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

AI Virtual Lab Engineers New SARS-CoV-2 Nanobodies

GBA1 Variants’ Impact on Parkinson’s: In Silico Analysis

Rotterdam Oncology: Premier Head & Neck Biobank

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.